Home/Pipeline/MyoRegulator PM-2200

MyoRegulator PM-2200

Amyotrophic Lateral Sclerosis (ALS)

Phase 2Active

Key Facts

Indication

Amyotrophic Lateral Sclerosis (ALS)

Phase

Phase 2

Status

Active

Company

PathMaker Neurosystems

About PathMaker Neurosystems

PathMaker Neurosystems is a Boston-based, private, clinical-stage medical device company pioneering a novel, non-invasive neuromodulation treatment for ALS and other neurological disorders. Founded in 2014, the company is advancing its lead product, the MyoRegulator PM-2200, based on its proprietary Multi-Site DCS technology, which is designed to normalize overactive neural pathways and reduce toxic protein aggregates in motor neurons. With a veteran management team and backing from scientific pioneers, PathMaker is positioned to address a significant unmet need in neurodegenerative diseases, though it faces the inherent risks of clinical development and regulatory pathways for a new device modality.

View full company profile

Therapeutic Areas

Amyotrophic Lateral Sclerosis Neurological Disorders

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

Drug	Company	Phase	Status
NPT520-34	Neuropore Therapies	Pre-clinical/Phase 1	Partnered (Biogen), Active
NUZ-001	Neurizon Therapeutics	Phase 2/3 (Platform Trial)	Active
CNM-Au8	Clene	Phase 2/3	Active
Masitinib	AB Science	Phase 3	Active
Undisclosed Program	Zhimeng Biopharma	Clinical	Active
SLS-005	Seelos Therapeutics	Platform Trial	Active (HEALEY ALS Platform Trial – Regimen E)
PMN442	ProMIS Neurosciences	Preclinical	Active
nAV-101	nVector	Pre-clinical	Active
ALTA-808	Alteron Therapeutics	Preclinical	IND-enabling studies launching
GM6	Genervon Biopharmaceuticals	Phase 2	Active
Lou Gehrig’s disease	Genclis	Discovery	Active
Treg-directed therapy for ALS	Iltoo Pharma	Pre-clinical	Active